Second-Line Docetaxel Improves Survival in Esophageal and Gastric Cancer (April 3, 2013)
Second-line treatment with docetaxel improves overall survival of patients with advanced esophageal and gastric cancer, according to the results of a study presented at the 2013 Gastrointestinal Cancers... Continue Reading
Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival... Continue Reading
The U.S. Food and Drug Administration (FDA) has expanded the approval of Herceptin® (trastuzumab) to include the initial treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal... Continue Reading
Gastric cancer forms in the tissues and lining of the stomach. Current treatment options include surgery, chemotherapy, and radiation. The current standard of care for metastatic gastric cancer is systemic... Continue Reading
Herceptin® Improves Survival with HER2-positive Gastric Cancer According to the results of a Phase III clinical trial presented at the 2009 annual meeting of the American Society of Clinical Oncology... Continue Reading